BR112022002123A2 - Composição farmacêutica para produzir uma quantidade segura de óxido nítrico e seu uso - Google Patents

Composição farmacêutica para produzir uma quantidade segura de óxido nítrico e seu uso

Info

Publication number
BR112022002123A2
BR112022002123A2 BR112022002123A BR112022002123A BR112022002123A2 BR 112022002123 A2 BR112022002123 A2 BR 112022002123A2 BR 112022002123 A BR112022002123 A BR 112022002123A BR 112022002123 A BR112022002123 A BR 112022002123A BR 112022002123 A2 BR112022002123 A2 BR 112022002123A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
nitric oxide
infections
safe amount
producing
Prior art date
Application number
BR112022002123A
Other languages
English (en)
Inventor
Kang Liu
Rui Gu
Yongzhi Cheng
Zenglin Lian
Original Assignee
Lianyungang Jinkang Hexin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lianyungang Jinkang Hexin Pharmaceutical Co Ltd filed Critical Lianyungang Jinkang Hexin Pharmaceutical Co Ltd
Publication of BR112022002123A2 publication Critical patent/BR112022002123A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

composição farmacêutica para produzir uma quantidade segura de óxido nítrico e seu uso. é descrita uma composição farmacêutica para produzir uma quantidade segura de óxido nítrico (no) in vivo, e seu uso. a composição farmacêutica compreende os seguintes componentes: um agente de redução de toxicidade de no, um extensor de no e um indutor de sintase de óxido nítrico. é provida uma composição farmacêutica que possui alta versatilidade e trata de forma extremamente eficaz as infecções por microrganismos patogênicos. é provida uma nova atividade medicinal do ácido 5-metiltetra-hidrofólico, nmn, e ácido de-hidroascórbico, tendo uma variedade de efeitos ativos no sistema imunológico causados por infecções por patógenos, sendo capaz de ser usado para tratar ou prevenir doenças causadas por infecções por vírus e outras infecções por patógenos.
BR112022002123A 2019-08-06 2020-08-06 Composição farmacêutica para produzir uma quantidade segura de óxido nítrico e seu uso BR112022002123A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910719544 2019-08-06
PCT/CN2020/107409 WO2021023263A1 (zh) 2019-08-06 2020-08-06 产生安全量的一氧化氮的药物组合物及其用途

Publications (1)

Publication Number Publication Date
BR112022002123A2 true BR112022002123A2 (pt) 2022-04-12

Family

ID=73500191

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022002123A BR112022002123A2 (pt) 2019-08-06 2020-08-06 Composição farmacêutica para produzir uma quantidade segura de óxido nítrico e seu uso
BR112022002156A BR112022002156A2 (pt) 2019-08-06 2020-08-06 Composição farmacêutica para tratamento da febre suína africana e seu uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022002156A BR112022002156A2 (pt) 2019-08-06 2020-08-06 Composição farmacêutica para tratamento da febre suína africana e seu uso

Country Status (7)

Country Link
US (2) US20220280508A1 (pt)
EP (2) EP4011371A4 (pt)
JP (2) JP2022545341A (pt)
CN (2) CN112007163B (pt)
AU (1) AU2020324248A1 (pt)
BR (2) BR112022002123A2 (pt)
WO (2) WO2021023263A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022021454A2 (pt) * 2020-04-23 2023-01-31 Thirty Respiratory Ltd Óxido nítrico ou composições liberadoras de óxido nítrico para uso no tratamento de sars-cov e sars-cov-2
CN113018306A (zh) * 2021-03-05 2021-06-25 中国人民解放军军事科学院军事医学研究院 烟酰胺单核苷酸在制备抑制SARS-CoV-2病毒易感性药物中的应用
CN113197902A (zh) * 2021-04-16 2021-08-03 连云港金康和信药业有限公司 6s-5-甲基四氢叶酸及其药学上可接受的盐用于增强免疫力的应用
CN114469913B (zh) * 2022-02-17 2024-03-22 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Tilorone用于预防/治疗非洲猪瘟病毒感染的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9318611D0 (en) * 1993-09-08 1993-10-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US6043268A (en) * 1994-06-29 2000-03-28 Hiroshi Maeda Agent for treatment of viral infections
EP1671630A3 (en) * 1999-02-05 2007-05-09 Angiogenix, Inc. L-Arginine based formulations for treating diseases and methods of using the same
US6544994B2 (en) * 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
US20080213403A1 (en) * 2002-07-25 2008-09-04 Alain Martin Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US20090047340A1 (en) * 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
CN101116670B (zh) * 2006-08-01 2010-11-10 广州和竺生物科技有限公司 可提供活性甲基或参与甲基转移的化合物作为制备治疗病毒性疾病的药的应用
US9359411B2 (en) * 2008-07-31 2016-06-07 Maw Hsing Biotech Co., Ltd. Yeast expressed classical swine fever virus glycoprotein E2 and use thereof
FI20095550A0 (fi) * 2009-05-19 2009-05-19 Bayer Schering Pharma Oy Vaginaalinen antojärjestelmä
JP5838969B2 (ja) * 2010-02-26 2016-01-06 味の素株式会社 低分子化合物とアルギニンとを含有するウイルス不活化用組成物
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US20130129680A1 (en) * 2011-11-23 2013-05-23 Thomas Christian Lines Method for treating hepatitis c virus infection using quercetin-containing compositions
CN103053863B (zh) * 2013-02-06 2013-10-02 韶关金苹果饲料有限公司 一种具有提高免疫力和除臭效果的猪用饲料添加剂
CN104232564A (zh) * 2014-05-12 2014-12-24 杭州国牧生物科技有限公司 一种st细胞制备猪瘟疫苗的培养基及其使用方法
CN106135895A (zh) * 2015-04-21 2016-11-23 淄博维克勋医药技术有限公司 一种营养补充剂
WO2017123418A1 (en) * 2016-01-11 2017-07-20 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
MX2018009543A (es) * 2016-02-03 2019-02-11 Quercegen Pharmaceuticals Llc Metodo para tratar la infección por el virus del zika con composiciones que contienen quercetina.
CN109350623A (zh) * 2018-05-25 2019-02-19 泓博元生命科技（深圳）有限公司 包含nadh和神经酰胺的抗衰老组合物及其制剂和制备方法与应用
CN108865995A (zh) * 2018-08-16 2018-11-23 深圳市拓普生物科技有限公司 促进脾脏来源的cd8阳性t细胞增殖的诱导培养组合物及其应用

Also Published As

Publication number Publication date
JP2022545341A (ja) 2022-10-27
EP4011372A4 (en) 2023-08-30
WO2021023264A1 (zh) 2021-02-11
EP4011371A1 (en) 2022-06-15
EP4011372A1 (en) 2022-06-15
EP4011371A4 (en) 2024-02-07
AU2020324248A1 (en) 2022-03-10
JP2022545771A (ja) 2022-10-31
CN112007163B (zh) 2023-07-28
CN114340609A (zh) 2022-04-12
CN112007163A (zh) 2020-12-01
US20220280508A1 (en) 2022-09-08
US20220273686A1 (en) 2022-09-01
WO2021023263A1 (zh) 2021-02-11
BR112022002156A2 (pt) 2022-06-07

Similar Documents

Publication Publication Date Title
BR112022002123A2 (pt) Composição farmacêutica para produzir uma quantidade segura de óxido nítrico e seu uso
CN104177950B (zh) 一种含有艾叶提取物的负离子抗菌乳胶漆
BR112018075960A2 (pt) moléculas de ácido nucleico para a redução de mrna de papd5 ou papd7 para o tratamento de infecção pela hepatite b
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
BR112018016341A2 (pt) solução de bloqueio do cateter e terapia de bloqueio do cateter
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
BR112022017308A2 (pt) Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral
BR9908617A (pt) Nitroto inorgânico e ácido orgânico em combinação como uma composição antiviral tópica.
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
SE0950390L (sv) System och process för tillverkning av en lösning med suspenderade fasta ämnen och användningar därför
BR112022010798A2 (pt) Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo
BR112022000957A2 (pt) Uso de progestógeno para inibir tempestade de citocina e composição compreendendo progestógeno
BR112021022283A2 (pt) Novas endolisinas de gardnerella e usos das mesmas
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
BR112015023806A2 (pt) Novos regimes de dosagem de celgosivir para o tratamento de dengue
CN102205077A (zh) 一种妇科外用洗液及其制备方法
ECSP20083454A (es) Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne
KNIGHT et al. The effect of antimicrobial drugs on the staphylococcal flora of hospital patients
Zheng et al. In vitro and in vivo antiviral effect of Fufang Yinhua Jiedu granules (FFYH) combined with oseltamivir against influenza A virus
CN110876740B (zh) volvalerenal K在修复皮肤破损中的用途
Rajam et al. Treatment-Resistant Syphilis: Short Review and Report of a Case
CN101513424B (zh) 一种治疗猪的无名高热病的注射液
CN106806514A (zh) 一种治疗肺炎的药物
CN104257978A (zh) 一种治疗附睾炎的中药组合物